Современная стратегия лечения болезни депонирования кристаллов пирофосфата кальция
https://doi.org/10.14412/1995-4484-2018-746-752
Аннотация
Об авторах
С. А. ВладимировРоссия
научный сотрудник лаборатории микрокристаллических артритов.
Москва, Россия 115522 Москва, Каширское шоссе, 34А.
М. С. Елисеев
Россия
заведующий лабораторией микрокристаллических артритов.
Москва, Россия 115522 Москва, Каширское шоссе, 34А.
Список литературы
1. Hollander JL, Jessar RA, McCarty DJ. Synovianalysis: an aid in arthritis diagnosis. Bull Rheum Dis. 1961;(12):263-4.
2. Кудаева ФМ, Владимиров СА, Елисеев МС и др. Особенности клинических проявлений болезни депонирования кристаллов пирофоасфата кальция. Научно-практическая ревматология. 2014;52(4):405-9 [Kudaeva FM, Vladimirov SA, Eliseev MS, et al. The clinical manifestations of calcium pyrophosphate crystal deposition disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):405-9 (In Russ.)]. doi: 10.14412/1995-4484-2014-405-409
3. Richette P, Bardin T, Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology (Oxford). 2009;48:711-5. doi: 10.1093/rheumatology/kep081
4. Doherty M. Calcium pyrophosphate dihydrate crystal-associated arthropathy. In: Hochberg M, ed. Rheumatology. Edinburgh: Mosby; 2003. P. 1937-50
5. Neame RL, Carr AJ, Muir K, Doherty M. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis. 2003;62:513-8. doi: 10.1136/ard.62.6.513
6. Felson DT, Anderson JJ, Naimark A, et al. The prevalence of chondrocalcinosis in the elderly and its association with knee osteoarthritis: the Framingham Study. J Rheumatol. 1989;16(9):1241-5.
7. Sanmarti R, Panella D, Brancos MA, et al. Prevalence of articular chondrocalcinosis in elderly subjects in a rural area of Catalonia. Ann Rheum Dis. 1993;52:418-22. doi: 10.1136/ard.52.6.418
8. Saadeh C. Calcium Pyrophosphate Deposition Disease. Medscape, 09.2009. Доступно по ссылке:
9. https://emedicine.medscape.com/article/330936-overview
10. Salaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol. 2005;23:819-28.
11. Елисеев МС, Владимиров СА. Распространенность и клинические особенности подагры и болезни депонирования пирофосфата кальция у пациентов с острым артритом. Научно-практическая ревматология. 2015;53(4):375-8 [Eliseev MS, Vladimirov SA. The prevalence and clinical features of gout and calcium pyrophosphate deposition disease in patients with acute arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;53(4):375-8 (In Russ.)]. doi: 10.14412/1995-4484-2015-375-378
12. Zhang W, Doherty M, Bardin T, Barskova V, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011;70:563-70. doi: 10.1136/ard.2010.139105
13. Rosenthal AK, Ryan LM. Crystal arthritis: calcium pyrophosphate deposition-nothing ‘pseudo’ about it! Nat Rev Rheumatol. 2011;7(5):257-8. doi: 10.1038/nrrheum.2011.50
14. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;6:29-42. doi: 10.1136/annrheumdis-2016-209707
15. Sivera F, Andres M, Pascual E. Current advances in therapies for calcium pyrophosphate crystal arthritis. Curr Opin Rheumatol. 2016;28(2):140-4. doi: 10.1097/BOR.0000000000000252
16. Doherty M, Dieppe PA. Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy. Ann Rheum Dis. 1983;42:106-7. doi: 10.1136/ard.42.Suppl_1.106
17. Ritter K, Kerr LD, Valeriano-Marcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol. 1994;21(4):696-9.
18. Daoussis D, Antonopoulos I, Yiannopoulos G, Andonopoulos AP. ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients. Joint Bone Spine. 2014;81(1):98-100. doi: 10.1016/j.jbspin.2013.05.006
19. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendation for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-24. doi: 10.1136/ard.2006.055269
20. Terkeltaub RA, Furst DE, Bennett K, et al. High-vs low-dosing of oral colchicine for early acute gout flare: Twenty-four hour outcome results of the first randomized, placebocontrolled, dose comparison colchicine trial. Arthritis Rheum. 2010 Apr;62(4):1060-8. doi: 10.1002/art.27327
21. Announ N, Guerne P-A. Treating diffilt crystal pyrophosphate dihydrate deposition disease. Curr Rheumatol Rep. 2008;10(3):228-34. doi: 10.1007/s11926-008-0037-2
22. Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol. 1986;13(4):804-5.
23. Das SK, Mishra K, Ramakrishnah S, et al. A randomized controlled trial to evaluate the slow-acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee. Osteoarthr Cartilage. 2002;10:247-52. doi: 10.1053/joca.2002.0516
24. Solomon DH, Husni ME, Libby PA, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen or naproxen: a secondary analysis of the PRECISION trial. Am J Med. 2017;130(12):1415-22 doi: 10.1016/j.amjmed.2017.06.028
25. Елисеев МС, Желябина ОВ. Сочетание подагры и болезни депонирования пирофосфатов кальция: трудности диагностики и лечения. РМЖ. Медицинское обозрение. 2017;(1):44-7 [Eliseev MS, Zhelyabina OV. The combination of gout and the disease of calcium pyrophosphate deposition: the difficulties of diagnosis and treatment. RMZh. Meditsinskoe Obozrenie. 2017;(1):44-7 (In Russ.)].
26. Елисеев МС, Владимиров СА. Применение мелоксикама (Амелотекс®) у больных пирофосфатной артропатией. Cовременная ревматология. 2011;5(3):34-6 [Eliseev MS, Vladimirov SA. Use of meloxicam (Amelotex®) in patients with pyrophosphate arthropathy. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2011;5(3):34-7 (In Russ.)]. doi: 10.14412/1996-7012-2011-682
27. Andres M, Sivera F, Pascual E. Therapy for CPPD: Options and Evidence. Curr Rheumatol Rep. 2018 Apr 19;20(6):31. doi: 10.1007/s11926-018-0739-z
28. Rosenthal AK. Update in calcium deposition diseases. Curr Opin Rheumatol. 2007;19(2):158-62. doi: 10.1097/BOR.0b013e3280145289
29. Werlen D, Gabay C, Vischer TL. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. Rev Rhum Engl Ed. 1996;63(4):248-54.
30. Roane DW, Harris MD, Carpenter MT, et al. Prospective use of intramuscular triamcinolone acetonide in pseudogout. J Rheumatol. 1997;24(6):1168-70.
31. Potvin F, Petitclerc E, Marceau F. Mechanisms of action of antimalarials in inflammation: induction of apoptosis in human endothelial cells. J Immun. 1997;158:1872-9.
32. Rothschild B, Yakubov LE. Prospective 6-month, doubleblind trial of hydroxychloroquine treatment of CPDD. Compr Ther. 1997 May;23(5):327-31.
33. Chollet-Janin A, Finckh A, Dudler J, Guerne PA. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007;56:688-92. doi: 10.1002/art.22389
34. Andres M, Sivera F, Pascual E. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol. 2012;18:234-6. doi: 10.1097/RHU.0b013e3182611471
35. Doan TH, Chevalier X, Leparc JM, et al. Premature enthusiasm for the use of methotrexate for refractory chondrocalcinosis: comment on the article by Chollet-Janin et al. Arthritis Rheum. 2008;58:2210-1. doi: 10.1002/art.23552
36. Finckh A, Mc Carthy GM, Madigan A, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014 Oct 15;16:458. doi: 10.1186/s13075-014-0458-4
37. Pascual E, Andres M, Sivera F. Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease? Arthritis Res Ther. 2015 Apr 1;17:89. doi: 10.1186/s13075-015-0598-1
38. Theiler G, Quehenberger F, Rainer F, et al. The detection of calcium pyrophosphate crystals in the synovial fluid of patients with rheumatoid arthritis using the cytospin technique: prevalence and clinical correlation. Rheumatol Int. 2014;34:137-9. doi: 10.1007/s00296-012-2608-9
39. Oliviero F, Scanu A, Galozzi P, et al. Prevalence of calcium pyrophosphate and monosodium urate crystals in synovial fluid of patients with previously diagnosed joint diseases. Joint Bone Spine. 2013;80:287-90. doi: 10.1016/j.jbspin.2012.08.006
40. Елисеев МС, Владимиров СА, Насонов ЕЛ. Применение метотрексата у больных с болезнью депонирования кристаллов пирофосфата кальция. Научно-практическая ревматология. 2018;56(2):196-201 [Eliseev MS, Vladimirov SA, Nasonov EL. Use of methotrexate in patients with calcium pyrophosphate crystal deposition disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(2):196-201 (In Russ.)]. doi: 10.14412/1995-4484-2018-196-201
41. Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77 [Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):60-77 (In Russ.)]. doi: 10.14412/1995-4484-2016-60-77
42. Елисеев МС, Барскова ВГ, Насонов ЕЛ. Канакинумаб (ингибитор интелейкина 1) – прорыв в возможностях противовоспалительной терапии при подагре. Научно-практическая ревматология. 2013;51(4):428-31 [Eliseev MS, Barskova VG, Nasonov EL. Canakinumab (an interleukin 1β inhibitor) is a breakthrough in the possibilities of anti-inflammatory therapy for gout. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(4):428-31 (In Russ.)]. doi: 10.14412/1995-4484-2013-1255
43. Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016;374:2575-84. doi: 10.1056/NEJMra1511117
44. McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum. 2008;58:631-3. doi: 10.1002/art.23119
45. Announ N, Palmer G, Guerne PA, Gabay C. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine. 2009;76:424-6. doi: 10.1016/j.jbspin.2009.01.001
46. Couderc M, Mathieu S, Glace B, Soubrier M. Efficacy of anakinra in articular chondrocalcinosis: report of three cases. Joint Bone Spine. 2012;79:330-1. doi: 10.1016/j.jbspin.2011.12.017
47. Molto A, Ea HK, Richette P, et al. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. Joint Bone Spine. 2012;79:621-3. doi: 10.1016/j.jbspin.2012.01.010
48. Diamantopoulos AP, Brodin C, Hetland H, Haugeberg G. Interleukin 1β blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment. J Clin Rheumatol. 2012;18:310-1. doi: 10.1097/RHU.0b013e31826149a2
49. Ottaviani S, Brunier L, Sibilia J, et al. Efficacy of anakinra in calcium pyrophosphate crystal induced arthritis: a report of 16 cases and review of the literature. Joint Bone Spine. 2013;80:178-82. doi: 10.1016/j.jbspin.2012.07.018
50. Aouba A, Deshayes S, Frenzel L, et al. Efficacy of anakinra for various types of crystal-induced arthritis in complex hospitalized patients: a case series and review of the literature. Mediat Inflamm. 2015;2015:792173. doi: 10.1155/2015/792173
51. Bruges-Armas J, Bettencourt BF, Couto AR, et al. Effectiveness and safety of infliximab in two cases of severe chondrocalcinosis: nine years of follow-up. Case Rep Rheumatol. 2014;2014:536856. doi: 10.1155/2014/536856
52. Quilis N, Andres M, Vela P, Pascual E. Interleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: two cases report. Joint Bone Spine. 2018 May;85(3):377-8. doi: 10.1016/j.jbspin.2017.04.008
53. Guerne PA, Terkeltaub R, Zuraw B, Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum. 1989;32:1443-52. doi: 10.1002/anr.1780321114
54. Danino O, Svetitsky S, Kenigsberg S, et al. Inhibition of nucleotide pyrophosphatase/phosphodiesterase 1: implications for developing a calcium pyrophosphate deposition disease modifying drug. Rheumatology (Oxford). 2018 Aug 1;57(8):1472-80. doi: 10.1093/rheumatology/key092
Рецензия
Для цитирования:
Владимиров С.А., Елисеев М.С. Современная стратегия лечения болезни депонирования кристаллов пирофосфата кальция. Научно-практическая ревматология. 2018;56(6):746-752. https://doi.org/10.14412/1995-4484-2018-746-752
For citation:
Vladimirov S.A., Eliseev M.S. Current strategy in the treatment of calcium pyrophosphate crystal deposition disease. Rheumatology Science and Practice. 2018;56(6):746-752. (In Russ.) https://doi.org/10.14412/1995-4484-2018-746-752